MedTrace Logo

Open-label Study of the Effects of Montelukast in Patients With Chronic Cough

NCT01754220 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2012-12-21

No results posted yet for this study

Summary

Montelukast, a leukotriene receptor antagonist, is likely to be effective in the treatment of chronic cough and this could be made objective by measuring cough threshold before and after two weeks of treatment.

Conditions

  • Coughing

Interventions

DRUG

Montelukast

Montelukast is a leukotriene receptor antagonist

Sponsors & Collaborators

  • Association Asthma, Bulgaria

    lead OTHER

Principal Investigators

  • Todor A Popov, MD, Phd · Association Asthma, Bulgaria

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Bulgaria

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01754220 on ClinicalTrials.gov